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MaBACKGROUND Stenosis of saphenous vein grafts (SVGs) after coronary artery bypass grafting (CABG) is common and
often requires percutaneous coronary interventions (PCI) for treatment. However, data for the effectiveness of drug-
eluting stents (DES) versus bare-metal stents (BMS) in SVG-PCI are unclear.
OBJECTIVES This study sought to examine the association between DES versus BMS used during SVG PCI and clinical
outcomes in the national Veterans Affairs integrated healthcare system.
METHODS We studied a national cohort of 2,471 post-CABG veterans undergoing SVG-PCI between 2008 and 2011 at
all Veterans Affairs hospitals and compared clinical outcomes of between those receiving DES and BMS. Clinical outcomes
included procedural complications, myocardial infarction (MI), and all-cause mortality. Comparisons were made in a
propensity-matched cohort using Cox proportional hazards regression models.
RESULTS DES were used in 1,549 SVG-PCI patients (63%) and the use of DES increased progressively with each cal-
endar year (50% in 2008 to 69% in 2011). Incidence of procedural complications was low and comparable in both groups
(2.8% among BMS vs. 2.3% among DES patients; p ¼ 0.54). During long-term (>2 years) follow-up, use of DES was
associated with lower mortality than BMS (hazard ratio [HR]: 0.72; 95% conﬁdence interval [CI]: 0.57 to 0.89) and
similar rates of MI (HR: 0.94; 95% CI: 0.71 to 1.24) in the propensity-matched cohort.
CONCLUSIONS In a national cohort of veterans, we observed widespread and increasing use of DES during SVG-PCI.
In long-term follow-up, compared with BMS, DES use was safe and effective in SVG-PCI patients. (J Am Coll Cardiol
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1826S aphenous vein graft (SVG) stenosis af-ter coronary artery bypass grafting(CABG) is common, occurring in as
many as 50% of patients at 5 years (1). Percuta-
neous intervention (PCI) and stent placement
in SVG (SVG-PCI) is routinely performed, with
SVG-PCI accounting for approximately 6%
of total PCI volume (2). However, there are
fundamental differences between the patho-
physiology of SVG stenosis and that of native
coronary artery stenosis, such as ﬁbro-
muscular hyperplasia from abnormal ﬂow
dynamics, excessive wall shear stress, and
suture site inﬂammatory response (3). There-
fore, the advantages and disadvantages of
drug-eluting stent (DES) versus bare-metal
stent (BMS) PCI in native coronary artery dis-
ease may not translate into SVG-PCI.SEE PAGE 1837There are limited data comparing DES and BMS in
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mber 30, 2011
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¼ drug-eluting stent(s); PCI ¼ percutaneous coronary
vein graft; VA ¼ Veterans Affairs.trials with conﬂicting results have been published to
date (4–7). These studies all included routine follow-
up angiography that can magnify the potential
beneﬁt of DES. In addition, the use of DES may
necessitate prolonged dual antiplatelet therapy,
placing patients at risk for bleeding. Given the risks
associated with DES use and the uncertain beneﬁt
compared with BMS in SVG-PCI, the role of DES in
SVG-PCI remains unclear.
The Veterans Affairs Clinical Assessment Reporting
and Tracking (VA-CART) program included all patient
and procedural data linked to longitudinal outcomes
for all PCIs performed in the national VA healthcare
system as part of a national quality assessment
and improvement program (8). Hence, VA-CART
provided a unique opportunity to assess the
comparative effectiveness and safety of DESs versus
that of BMSs in a large national contemporary cohort
of patients receiving SVG-PCI. Speciﬁcally, we com-
pared procedure-related in-laboratory complications,
myocardial infarction (MI), and mortality in those
who received DES with those who received BMS
during SVG-PCI. This study will help provide insight
into the impact of stent type on long-term outcomes
and address knowledge gaps in the contemporary
clinical practice of SVG-PCI.
METHODS
STUDY DESIGN, SETTING, AND POPULATION. This
was a retrospective study of a national cohort of post-
CABG veterans undergoing SVG- PCI at all 63 VA PCI
centers from October 1, 2007 through September 30,
2011 (Figure 1). Procedures with missing procedural
details, such as indication for procedure or stent
type were excluded, as were patients who received
both BMS and DES. The ﬁrst SVG-PCI procedure
during the study period was deﬁned as the index
procedure, and outcomes were assessed through
September 30, 2012.
DATA SOURCE. The VA-CART program is a national
clinical quality improvement program for VA cathe-
terization laboratories (CL). It uses a software appli-
cation (CART-CL) for medical record documentation
of key patient and procedural data for all procedures
conducted in the VA catheterization laboratories
nationwide. CART-CL is embedded in the VA electronic
health record, allowing for linkage to longitudinal
outcome data. In addition, it is also linked to fee-based
data to account for veterans who receive non-VA care.
Data elements in CART-CL are standardized and
based on American College of Cardiology’s national
cardiovascular data catheterization-PCI registry (9).
A dedicated staff provides continuous monitoring,
TABLE 1 Temporal Trends in Stent Use During SVG PCI Performed During 2008–2011 in the VA Health System Nationwide
Use All 2008 2009 2010 2011
All PCIs Non-SVG 37,903 (91.0) 7,855 (90.2) 8,660 (90.3) 10,458 (91.4) 10,930 (91.7)
SVG 3,762 (9.0) 856 (9.8) 935 (9.7) 988 (8.6) 983 (8.3)
Study cohort BMS 922 (37.3) 280 (50.1) 228 (35.7) 218 (34.3) 196 (30.7)
DES 1549 (62.7) 279 (49.9) 410 (64.3) 417 (65.7) 443 (69.3)
Values are n (%). The p value for the overall temporal trend from 2008 to 2011 was <0.001.
BMS ¼ bare-metal stent(s); DES ¼ drug-eluting stent(s); FY ¼ ﬁscal year; PCI ¼ percutaneous coronary intervention; SVG ¼ saphenous vein graft.
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1827maintenance, and updating of the application. Quality
checks of CART data are periodically conducted for
completeness and accuracy. Additional details of
CART and the validity, completeness, and timeliness
of the CART data were previously described (8).
EXPOSURE VARIABLE. The primary exposure vari-
able of interest was type of stent received during the
index SVG-PCI. Stents used during the procedure
were characterized as BMS or DES, and patients
receiving both stent types were excluded from theTABLE 2 Baseline Demographic and Clinical Characteristics of the Ov
Unmatched Cohort
All
(n ¼ 2,471)
BMS
(n ¼ 922)
DES
(n ¼ 1,549)
Age, yrs 67 (62–75) 68 (62–77) 66 (62–75)
Male 2,456 (99.4) 921 (99.9) 1,535 (99.1)
White 2,250 (91.1) 846 (91.8) 1,404 (90.6)
Hypertension 2,404 (97.3) 894 (97.0) 1,510 (97.5)
Hyperlipidemia 2,385 (96.5) 881 (95.6) 1,504 (97.1)
Diabetes mellitus 1,474 (59.7) 526 (57.0) 948 (61.2)
Tobacco use 1,413 (57.2) 516 (56.0) 897 (57.9)
Obese 1,156 (46.8) 390 (42.3) 766 (49.5)
CHF 914 (37.0) 359 (38.9) 555 (35.8)
COPD 624 (25.3) 247 (26.8) 377 (24.3)
Stroke/TIA 741 (30.0) 285 (30.9) 456 (29.4)
PVD 903 (36.5) 341 (37.0) 562 (36.3)
Kidney disease 412 (16.7) 170 (18.4) 242 (15.6)
Previous PCI 1,752 (70.9) 659 (71.5) 1,093 (70.6)
Previous MI 1,265 (51.2) 455 (49.3) 810 (52.3)
PCI indication
STEMI 101 (4.1) 51 (5.5) 50 (3.2)
NSTEMI 667 (27.0) 272 (28.5) 395 (25.5)
Unstable angina 732 (29.6) 258 (28.0) 474 (30.6)
ACS-unknown details 55 (2.2) 27 (2.9) 28 (1.8)
Stable angina 651 (26.3) 190 (20.6) 461 (29.8)
Chest pain 92 (3.7) 38 (4.1) 54 (3.5)
No angina 36 (1.5) 21 (2.3) 15 (1.0)
Other 137 (5.5) 68 (7.4) 69 (4.5)
Cardiogenic shock 26 (1.1) 11 (1.2) 15 (1.0)
Values are median (interquartile range) or n (%).
ACS ¼ acute coronary syndrome; CHF ¼ congestive heart failure; COPD ¼ chronic ob
elevation myocardial infarction; PVD ¼ peripheral vascular disease; STEMI ¼ ST-segment
in Table 1.study cohort. Stent type is a discrete data element
selected by the physicians from a pull-down list in the
CART-CL software application. First-generation DES
was deﬁned as paclitaxel-eluting or sirolimus-eluting
stent, and second-generation DES was deﬁned as
everolimus-eluting or zotarolimus-eluting stent.
Quality and validity of data entered into CART were
previously described (8).
OUTCOME ASSESSMENT. Outcomes assessed included
both short-term (procedure-related in-laboratoryerall and Propensity-Matched Cohorts
Propensity-Matched Cohort
p Value
All
(n ¼ 1,796)
BMS
(n ¼ 895)
DES
(n ¼ 901) p Value
<0.001 68 (62–76) 68 (62–76) 68 (62–76) 0.76
0.44 1,721 (95.8) 862 (96.3) 859 (95.3) 0.45
0.59 1,579 (87.9) 788 (88.0) 791 (87.8) 0.80
0.13 1,676 (93.3) 838 (93.6) 838 (93.0) 1.00
0.01 1,660 (92.4) 829 (92.6) 831 (92.2) 0.81
0.03 987 (55.0) 500 (55.9) 487 (54.1) 0.53
0.28 991 (55.2) 484 (54.1) 507 (56.3) 0.26
<0.001 769 (42.8) 372 (41.6) 397 (44.1) 0.23
0.15 644 (35.9) 337 (37.7) 307 (34.1) 0.14
0.20 447 (24.9) 227 (25.4) 220 (24.4) 0.70
0.49 543 (30.2) 269 (30.1) 274 (30.4) 0.80
0.80 650 (36.2) 325 (36.3) 325 (36.1) 1.00
0.08 294 (16.4) 159 (17.8) 135 (15.0) 0.12
0.77 1,248 (69.5) 622 (69.5) 626 (69.5) 0.83
0.12 874 (48.7) 426 (47.6) 448 (49.7) 0.29
<0.001 82 (4.6) 41 (4.6) 41 (4.6) 0.70
515 (28.7) 252 (28.1) 263 (29.2)
491 (27.3) 253 (28.3) 238 (26.4)
39 (2.2) 24 (2.7) 15 (1.7)
393 (21.9) 187 (20.9) 206 (22.9)
64 (3.6) 35 (3.9) 29 (3.2)
29 (1.6) 16 (1.8) 13 (1.4)
115 (6.4) 56 (6.3) 59 (6.5)
0.61 21 (1.2) 9 (1.0) 12 (1.3) 0.51
structive pulmonary disease; MI ¼ myocardial infarction; NSTEMI ¼ non-ST segment
elevation myocardial infarction; TIA ¼ transient ischemic attack; other abbreviations as
TABLE 3 Procedural
Target native vessel
Diagonal
LAD
OM/ramus/LPL
RCA/PDA/RPL/RPAV
Other
Unknown
Graft lesion location
Anastomotic
Aortic-Ostial
Body
Unknown
Procedure details
Fluoroscopy time, m
Contrast, mL
Embolic protection d
Number of stents
1
2
3
>3
Pre-TIMI ﬂow grade
0
1
2
3
Unknown
Post-TIMI ﬂow grade
0
1
2
3
Unknown
Values are n (%) or median
LAD ¼ left anterior desce
RPL ¼ right posterolateral
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1828complications) and long-term (mortality and MI)
outcomes.
1. Procedure-related in-laboratory complications. We
assessed the incidence of death, periprocedural MI,
no-reﬂow, dissection, perforation, and acute target
vessel closure. The treating physician directly
entered this information into CART-CL as a
discrete data element (8).
2. Myocardial infarction. We used the VA national pa-
tient care database to assess the occurrence and
timing of MI hospitalizations that were based on
validated inpatient primary International Classiﬁ-
cation of Diseases, ninth revision (ICD-9) discharge
diagnosis codes (10). A random sample of MICharacteristics of the Entire and Propensity-Matched Cohorts
Unmatched Cohort
N ¼ 2,471
All
BMS
(n ¼ 922)
DES
(n ¼ 1,549) p Value
<0.01
413 (14.4) 116 (10.9) 297 (16.4)
162 (5.7) 63 (5.9) 99 (5.5)
1,203 (42.0) 451 (42.5) 752 (41.6)
1,048 (36.6) 414 (39.1) 634 (35.1)
24 (0.8) 8 (0.8) 16 (0.9)
17 (0.6) 8 (0.8) 9 (0.5)
<0.01
314 (11.0) 76 (7.2) 238 (13.2)
598 (20.9) 217 (20.5) 381 (21.1)
1,875 (65.4) 751 (70.8) 1,124 (62.2)
80 (2.8) 16 (1.5) 64 (3.5)
in 25 (17–39) 26 (17–40) 25 (16–37) 0.01
230 (150–335) 235 (160–350) 230 (150–327) 0.20
evice 936 (37.9) 360 (38.9) 576 (37.3) 0.41
0.22
2,421 (84.4) 889 (83.9) 1,532 (84.8)
326 (11.4) 116 (10.9) 210 (11.6)
78 (2.7) 36 (3.4) 42 (2.3)
42 (1.5) 19 (1.8) 23 (1.3)
0.04
121 (4.2) 54 (5.1) 67 (3.7)
144 (5.0) 54 (5.1) 67 (3.7)
516 (18.0) 197 (18.6) 319 (17.7)
1,859 (64.8) 690 (65.1) 1,169 (64.7)
227 (7.9) 65 (6.1) 162 (9.0)
<0.01
19 (0.7) 10 (0.9) 9 (0.5)
16 (0.6) 10 (0.9) 6 (0.3)
59 (2.1) 30 (2.8) 29 (1.6)
2,544 (88.7) 943 (89.0) 1,601 (88.6)
229 (8.0) 67 (6.3) 162 (9.0)
(IQR).
nding artery; LPL¼ left posterolateral artery; OM ¼ obtuse marginal; PDA ¼ posterior descen
artery; TIMI ¼ Thrombolysis In Myocardial Infarction; other abbreviations as in Tables 1 anpatients also underwent individual chart review
to validate this outcome in accordance with the
third universal deﬁnition of MI (11). Codes for MI
hospitalizations during the ﬁrst 14 days after
PCI discharge date were subsequently disregarded
because a review of cases showed that most of these
codes were related to the index hospitalization.
3. All-cause mortality. The VA vital status ﬁle was
used to assess mortality outcome. This ﬁle has
98.3% sensitivity and 97.6% exact agreement with
dates compared with the National Death Index (12).
STATISTICAL ANALYSIS. Comparison of baseline
characteristics and in-laboratory complications be-
tween the DES and BMS groups were performed usingPropensity-Matched Cohort
N ¼ 1,796
All
BMS
(n ¼ 895)
DES
(n ¼ 901) p Value
0.04
266 (13.3) 109 (11.0) 157 (15.5)
118 (5.9) 56 (5.7) 62 (6.1)
845 (42.3) 419 (42.4) 426 (42.1)
738 (36.9) 390 (39.4) 348 (34.4)
19 (1.0) 8 (0.8) 11 (1.1)
14 (0.7) 7 (0.7) 7 (0.7)
<0.001
202 (1.1) 72 (3.7) 130 (12.9)
414 (20.7) 208 (21.0) 206 (20.4)
1,330 (66.5) 694 (70.2) 636 (62.9)
54 (2.7) 15 (1.5) 39 (3.9)
25 (17–39) 26 (17–40) 25 (16–37) 0.08
230 (160–341) 232 (160–350) 230 (159–334) 0.57
647 (37.4) 332 (38.4) 315 (36.5) 0.40
0.18
1,676 (83.8) 827 (83.6) 849 (84.0)
233 (11.7) 108 (10.9) 125 (12.4)
58 (2.9) 36 (3.6) 22 (2.2)
33 (1.7) 18 (1.8) 15 (1.5)
0.09
96 (4.8) 52 (5.3) 44 (4.4)
94 (4.7) 51 (5.2) 43 (4.3)
376 (18.8) 184 (18.6) 192 (19.0)
1,284 (64.2) 643 (65.0) 641 (63.4)
150 (7.5) 59 (6.0) 91 (9.0)
<0.01
14 (0.7) 10 (1.0) 4 (0.4)
15 (0.8) 10 (1.0) 5 (0.5)
40 (2.0) 26 (2.6) 14 (1.4)
1,778 (88.9) 882 (89.2) 896 (88.6)
153 (7.7) 61 (6.2) 92 (9.1)
ding artery; RCA ¼ right coronary artery; RPAV ¼ right posterior arteriovenous artery;
d 2.
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1829Pearson chi-square or Fischer’s exact test for categor-
ical variables and Mann-Whitney-Wilcoxon nonpara-
metric tests for continuous variables. Binary logistic
regression was used to estimate propensity for
receiving a DES. The following variables were consid-
ered for inclusion in the propensity score model:
age, sex, white race, ethnicity, cardiogenic shock
on arrival, PCI indication, diabetes, hypertension,
hyperlipidemia, history of tobacco use, cerebrovascu-
lar disease, peripheral vascular disease (PVD), previ-
ous PCI, previous MI, and fall risk. These variables
were included on the basis of clinical rationale and/or
previous studies. Fall risk was a categorical variable
on the basis of the Morse Fall Scale results from
6 months before the procedure, with a score of <25
being low-risk; 25 to 45, moderate-risk; and >45, high-
risk (13). When the Morse Fall Scale was missing, we
assumed low risk. There was adequate overlap in pro-
pensity scores for DES and BMS cases. A greedy 5-to-1
matching algorithm was used to create a 1-to-1
matched cohort (i.e., 1 BMS case matched to 1 DES
case). Balance in the matched cohort was evaluated
using standardized differences for all covariates.
An absolute difference of <10% in all variables is
commonly considered adequate balance (14). The
maximum standardized difference in the chosen
cohort was 7.8%. The C statistic for the propensity
score model was 0.6319. We compared outcomes of
patients receiving DES versus those receiving BMS in
the propensity-matched cohort. We used the Kaplan-
Meier method to determine event-free survival and
compared the 2 groups using the log-rank test, survival
curves, and the estimated event rates at 1 and 2 years.TABLE 4 Procedure-Related In-Laboratory Complications Seen in the
Complication
Unmatched Cohort
All
(n ¼ 2,471)
BMS
(n ¼ 922)
DES
(n ¼ 1,549)
No complication 2,409 (97.5) 900 (97.6) 1,509 (97.4)
Dysrhythmia 19 (0.8) 10 (1.1) 9 (0.6)
Periprocedural MI 12 (0.5) 9 (1.0) 3 (0.2)
Pulmonary edema 2 (0.1) 1 (0.1) 1 (0.1)
Cardiogenic shock 3 (0.1) 3 (0.3) 0 (0)
Stroke 1 (0.04) 0 (0) 1 (0.1)
Death during procedure 1 (0.04) 0 (0) 1 (0.1)
No reﬂow 82 (3.3) 45 (4.9) 37 (2.4)
Dissection 15 (0.6) 3 (0.3) 12 (0.8)
Perforation 13 (0.5) 10 (1.1) 3 (0.2)
Acute closure 5 (0.2) 4 (0.4) 1 (0.1)
Successful reopening 2 (0.1) 1 (0.1) 1 (0.1)
Other complications 27 (1.1) 5 (0.5) 22 (1.4)
Values are n (%).
Abbreviations as in Tables 1 and 2.We also ﬁt Cox proportional hazard models in the
propensity-matched cohort, with stent type as the
predictor and robust sandwich covariance matrix
estimates to account for intrahospital dependence
(15). In order to evaluate the proportional hazards
assumption in the Cox model, we used a Kolmogorov-
type supremum test of proportionality (16). These
diagnostic results indicated that the relationship
between stent type and outcomes of interest met the
proportional hazards assumption. Because a 1-to-1
match does not include the entire study cohort,
we also performed similar comparisons using the
entire study cohort with stabilized inverse probability
weighting analysis as a sensitivity analysis (17).
Our results remained similar and hence are not
presented. We performed 2 additional sensitivity
analyses involving the Cox proportional hazards
models described above. First, we included target
native vessel and lesion location as predictors in the
outcome models in addition to stent type. These were
not included in the propensity model because they
are procedural factors, but they did differ by stent
type after propensity matching. Second, we included
only stent type as a predictor, as in the main analysis,
but we stratiﬁed the DES group by DES generation.
First-generation DES included paclitaxel-eluting
and sirolimus-eluting stents, and second-generation
DES included everolimus-eluting and zotarolimus-
eluting stents.
For all analyses reported, p values are 2-sided and
p values <0.05 were considered signiﬁcant. All ana-
lyses were performed using SAS software version 9.3
(SAS Institute, Cary, NC). Institutional Review BoardsStudy Cohort Stratiﬁed by Stent Type
Propensity-Matched Cohort
p Value
All
(n ¼ 1,796)
BMS
(n ¼ 895)
DES
(n ¼ 901) p Value
0.63 1,684 (93.8) 840 (93.9) 844 (93.7) 0.54
0.17 16 (0.9) 10 (1.1) 6 (0.7) 0.32
0.01 10 (0.6) 8 (0.9) 2 (0.2) 0.06
1.00 2 (0.1) 1 (0.1) 1 (0.1) 1.00
0.05 3 (0.2) 3 (0.3) 0 (0) 0.25
1.00 1 (0.1) 0 (0) 1 (0.1) 1.00
1.00 1 (0.1) 0 (0) 1 (0.1) 1.00
<0.001 63 (3.5) 42 (4.7) 21 (2.3) 0.01
0.19 11 (0.6) 3 (0.3) 8 (0.9) 0.23
0.01 11 (0.6) 10 (1.1) 1 (0.1) 0.01
0.07 5 (0.3) 4 (0.4) 1 (0.1) 0.37
1.00 2 (0.1) 1 (0.1) 1 (0.1) 1.00
0.04 14 (0.8) 5 (0.6) 9 (1.0) 0.28
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7.75 (6.20, 9.70)BMS
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Kaplan-Meier curves are shown for probability of experiencing myocardial infarction or mortality in the propensity-matched cohort.
BMS ¼ bare-metal stent(s); DES ¼ drug-eluting stent(s); MI ¼ myocardial infarction.
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approved this study.
RESULTS
PATIENT POPULATION. Between October 1, 2007 and
September 30, 2011, a total of 3,762 SVG interventions
were performed nationwide in the VA healthcare
system. Those patients with previous SVG in-
terventions were excluded, and 2,825 new patients
who underwent index SVG-PCI (ﬁrst SVG-PCI proce-
dure during the study period) were identiﬁed. After
excluding 176 patients who did not receive a stent
and 178 patients who received both BMS and DES,
the ﬁnal cohort included 2,471 patients (65.7%),and the propensity-matched cohort had 1,796
patients (47.7%) (Figure 1), matching 1 BMS patient
to 1 DES patient. Overall, DES were used more
frequently, increasing from 50% of SVG-PCIs in 2008
to 69% by 2011 (Table 1). Of those receiving a DES,
34% (n ¼ 519) received ﬁrst-generation DES, and
the remainder (n ¼ 1030 [66%]) received second-
generation DES.
BASELINE CHARACTERISTICS. Table 2 describes the
baseline pre-procedural characteristics for the entire
cohort and for the propensity-matched cohort. The
mean age of veterans undergoing SVG-PCI was 67
years, 99.4% were males, and 91% were Caucasian.
Compared with patients receiving BMS, patients
receiving DES were younger (68 vs. 66 years,
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FIGURE 2 Kaplan-Meier Curves for Probability of
Experiencing Myocardial Infarction in the
Propensity-Matched Cohort
MI ¼ myocardial infarction; other abbreviations as in Figure 1.
TABLE 5 Adjusted Mortality and Myocardial Infarction Rates Seen
in the Study Cohort Stratiﬁed by Stent Type
Mortality
HR (95% CI)
Myocardial Infarction
HR (95% CI)
DES 2nd generation vs. BMS 0.65 (0.50–0.84) 1.00 (0.72–1.36)
DES 1st generation vs. BMS 0.78 (0.61–1.00) 0.88 (0.62–1.23)
DES 2nd generation vs.
1st generation
0.83 (0.66–1.06) 1.13 (0.81–1.58)
1st-generation DES include paclitaxel-eluting and sirolimus-eluting stents; 2nd-generation stents
refer to everolimus-eluting and zotarolimus-eluting stents.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.
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1831respectively; p <0.001) but were more likely to
have hyperlipidemia (95.6% vs. 97.1%, respectively;
p ¼ 0.01) and diabetes mellitus (57.0% vs. 61.2%,
respectively; p ¼ 0.03). There were no signiﬁcant
differences between baseline characteristics of the 2
comparison groups after propensity matching, and
the maximum standardized difference was 7.8% (data
not shown).
PROCEDURAL CHARACTERISTICS. Table 3 shows
baseline comparisons of procedural characteristics for
the overall and propensity-matched cohorts. The most
common native vessel territories receiving SVG-PCI
were the circumﬂex/ramus, followed by the right cor-
onary artery. Patients receiving SVG-PCI in the right
coronary artery territory were more likely to receive a
BMS both in the overall and propensity-matched
cohorts. Conversely, those receiving SVG-PCI in the
diagonal territory were more likely to receive a DES.
Furthermore, the graft lesion location in patients
receiving a BMS was more likely to be in the SVG body
and less likely to be anastomotic, compared with those
receiving a DES. Overall, an embolic protection device
was used in a third of all SVG-PCIs, and there were no
differences in the use of embolic protection by stent
type in either the overall or propensity-matched
cohorts. Use of contrast medium was also similar in
both (DES and BMS) stent subgroups. Additionally,
there were no signiﬁcant differences in number of
stents placed during index SVG-PCI.
CLINICAL OUTCOMES. Procedure-related in-laboratory
complications. Table 4 shows all reported procedure-
related in-laboratory complications for the overall
and propensity-matched cohorts. The incidence of
any procedure-related in-laboratory complication in
the overall cohorts was 2.5%, with no differences by
stent type. No-reﬂow was the most common peri-
procedural complication and was noted in 82 (3.3%)
patients overall, with a higher incidence in patients
receiving a BMS compared with those receiving DES
(4.9% vs. 2.4%, respectively; p < 0.001), even after
propensity matching (4.7% vs. 2.3%, respectively; p ¼
0.01). Periprocedural MI and dissection were noted
in 19 patients (0.8%) and 15 patients (0.6%), respec-
tively. Compared with patients receiving BMS, the
incidence rates of periprocedural MI and dissection
were similar after propensity matching among those
receiving a DES. Vessel perforation during SVG-PCI
was seen in 13 patients (0.5%) with a signiﬁcantly
higher incidence in the BMS group before (10 vs. 3
patients, respectively; p ¼ 0.01) and after (10 vs. 1
patient, respectively; p ¼ 0.01) propensity matching.
Furthermore, there was only 1 periprocedural death
in the overall cohort. There were no signiﬁcantdifferences in the incidence rates of procedural
dysrhythmia, pulmonary edema, cardiogenic shock,
or stroke in the 2 comparison groups.
Myocard ia l infarct ion . In the year following PCI,
there were 119 MI events (6.6%) in the propensity-
matched cohort; 67 (7.5%) among BMS patients, and
52 (5.8%) among DES patients. Kaplan-Meier esti-
mated 1-year MI event rates in the propensity-
matched cohort were similar to the overall crude
rates. In the propensity-matched cohort, there were
no differences in the hazard of experiencing MI in
patients receiving a DES compared with those
receiving a BMS (hazard ratio [HR]: 0.94; 95%
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1832conﬁdence interval [CI]: 0.71 to 1.24) (Central
Illustration) over a mean follow-up of 30 months.
These results remained similar after adjusting for
individual lesion location and target native vessel
(HR: 0.98; 95% CI: 0.74 to 1.29). Similarly, no signif-
icant differences in MI rates were noted between
patients receiving second-generation DES and those
receiving ﬁrst-generation DES (Figure 2, Table 5).
Morta l i ty . In the year following PCI, there were 177
deaths (9.9%) in the propensity-matched cohort: 101
(11.3%) among BMS patients and 76 (8.4%) among
DES patients (p ¼ 0.04). In the propensity-matched
cohort, patients receiving DES were less likely to
experience mortality (HR: 0.72; 95% CI: 0.57 to 0.89)
(Central Illustration) compared with patients with
BMS SVG-PCI over a mean follow-up of 33 months.
These results remained unchanged, even after
including individual lesion location and target
native vessel (HR: 0.71; 95% CI: 0.56 to 0.89).
Repeat analysis after stratifying the DES cohort into
ﬁrst-generation and second-generation DES showed
that patients receiving second-generation DES had
lower mortality rates, but this difference in mortal-
ity between second-generation and ﬁrst-generation
DES was not statistically signiﬁcant (Figure 3,
Table 5).1.00
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FIGURE 3 Kaplan-Meier Curves for Probability of Mortality
in the Propensity-Matched Cohort
Abbreviations as in Figure 1.DISCUSSION
The objective of this study was to describe contem-
porary patterns of stent use and outcomes among
veterans undergoing SVG-PCI nationwide. We ob-
served that DES were used twice as often as BMS
during SVG-PCI and that DES use increased over time
compared with BMS. Overall complication rates were
low and did not differ by stent type. We observed
lower all-cause mortality and similar MI rates with
DES than with BMS on longitudinal follow-up after
propensity matching. Therefore, the safety of DES
versus BMS is observed in patients undergoing SVG-
PCI and is associated with similar rates of MI and
reduced rates of death.
PREVIOUS STUDIES. Although both randomized
controlled trials and observational studies have
attempted to address the question of optimal stent
type for SVG-PCI, conﬂicting results have been seen
with the 2 study designs. In the RRISC (Reduction of
Restenosis In Saphenous vein grafts with Cypher
stent) trial, despite a reduction in 6-month restenosis
and repeat revascularization rate, higher mortality at
32 months in patients receiving DES raised concerns
about their safety in SVG-PCI (6,7). However, there
were no deaths among patients receiving BMS during
the follow-up period, and patients receiving DES were
mandated to receive dual anti-platelet therapy for
only 2 months, which could potentially explain
higher rates of mortality in the DES group. The SOS
(Stenting of Saphenous Vein Grafts) trial was powered
to examine differences in angiographic outcomes
only; hence, there were no signiﬁcant differences
detected in clinical outcomes between patients
receiving DES versus BMS (4). More recently, in the
ISAR-CABG (drug-eluting versus bare-metal stents in
saphenous vein graft lesions) trial, the use of DES was
associated with lower risk of a composite of death,
MI, and target lesion revascularization (TLR) (5).
However, the follow-up duration was shorter (12
months) than in the RRISC trial. Subsequently,
smaller observational studies and their meta-analyses
have compared DES with BMS in SVG-PCI and showed
lower TLR and target vessel revascularization (TVR),
but those studies were either underpowered or
too heterogeneous to draw any conclusions about
long-term safety (mortality) of DES in such patients
(5,18–22). Table 6 (4–7,15,18,20,23–39) summarizes the
existing evidence comparing DES versus BMS and how
they differ from our study. Overall, given the lack of
larger original studies, this reduction in TVR or TLR
with DES use has never been consistently extended to
mortality and major cardiovascular outcomes.
TABLE 6 Summary of Existing Evidence Comparing DES With BMS in SVG-PCI
First Author (Ref. #)
Number of
Patients
Study Endpoints
Follow-Up
Duration Results LimitationsBMS DES
Retrospective cohort
Assali et al. (23) 43 68 TLR, TVR, MI, death 24 months DES with lower TLR, TVR. Statistically
non-signiﬁcant difference for
death and MI.
Small sample size, underpowered
for death and MI as outcomes.
Bansal et al. (24) 72 37 Death, MI, restenosis, stent
thrombosis, TLR, TVR
36 months No difference between DES and BMS
for any outcome assessed.
Small sample size, underpowered
to assess differences in endpoints.
Gioia et al. (25) 72 99 Death, STEMI, TLR, TVR 24 months No difference between DES and BMS
for any outcome assessed.
Small sample size, underpowered
to assess differences in endpoints,
matched for only 2 variables.
Goswami et al. (26) 95 284 Mortality, MI, TLR,
stent thrombosis
36 months No difference between DES and BMS
for any outcome assessed.
Small sample size, underpowered
to assess differences in endpoints.
Kaplan et al. (27) 33 37 TLR, TVR, mortality, MI,
composite of all as MACE
12 months DES use associated with lower TLR,
TVR and MACE. No difference
for MI and death.
Only ostial SVG lesions assessed.
Short follow-up, small size,
underpowered to assess
differences for death and MI.
Lee et al. (15) 84 139 Death, MI, TVR 9 months Lower unadjusted death, TVR, MI with
DES use. Multivariable adjustment
not possible.
Small size, very few events
(4 deaths, 23 MI, and 55 TVR),
short duration of follow-up.
Lozano et al. (28) 113 98 Death, TVR 30 months No difference between DES and BMS
for any outcome assessed.
Small size, few events, historical
BMS group used as control.
Minutello et al. (29) 50 59 Death, MI, TVR, TLR,
Stent thrombosis
20 months Lower TVR with DES use. No difference
between BMS and DES for other
outcomes.
Historical BMS cohort, smaller
sample size and shorter duration
of follow-up, underpowered to
detect differences in outcomes.
Okabe et al. (20) 344 138 TLR, TVR, death, MI,
stent thrombosis
12 months No difference between DES and BMS
for any outcome assessed.
Small size, underpowered to
assess difference.
Ramana et al. (30) 170 131 TLR, TVR, death, MI, composite
of all as MACE
34 months Unadjusted event rates lower in DES
for all outcomes. No difference
between BMS and DES for any
outcome assessed after
multivariable adjustment.
Small size, underpowered to
assess difference.
van Twisk et al. (31) 128 122 Mortality, composite of
mortality, MI, TVR
48 months No difference between DES and BMS
for any outcome assessed.
Small size, underpowered to
assess difference.
Prospective cohort
Brodie et al. (18) 343 785 TVR, TLR, death, MI, death/MI,
death/MI/TVR
24 months DES with lower death, TVR and death/
MI/TVR. No difference for MI only,
TLR and death/MI.
Smaller sample size compared
with our study.
Chu et al. (32) 57 48 Death, MI, TLR, TVR, TLR/MACE,
TVR/MACE
12 months No difference between DES and BMS
for any outcome assessed.
Smaller sample size and shorter
duration of follow-up, lack
of propensity matching or
multivariable adjustment
in examining association.
Ellis et al. (33) 175 175 TVR, death 12 months No difference in TVR/death. Smaller sample size and shorter
duration of follow-up.
Ge et al. (34) 89 61 Death, MI, TLR, TVR 6 months DES use associated with fewer TLR
and TVR. No difference for MI, death.
Smaller sample size and shorter
duration of follow-up, lack
of propensity matching in
examining association.
Hoffmann et al. (35) 60 60 MACE (composite of MI, TLR,
death, MI, TVR), TLR
6 months DES use associated with lesser
MACE and TLR.
Smaller sample size, short
duration of follow-up.
Shishehbor et al. (36) 349 217 Composite of mortality, MI, TLR 35 months No difference in outcome between
DES and BMS.
Small cohort size. Historical
BMS cohort used.
Vignali et al. (37) 288 72 MACE (composite of mortality,
re-infarction, TVR)
12 months No difference in outcome between
DES and BMS.
Smaller sample size, short duration
of follow-up, underpowered
to assess difference.
Wöhrle et al. (38) 26 13 MACE (composite of mortality,
TVR, and MI)
12 months DES use associated with lower MACE. Small sample size, short follow-up
duration.
Continued on the next page
J A C C V O L . 6 4 , N O . 1 7 , 2 0 1 4 Aggarwal et al.
O C T O B E R 2 8 , 2 0 1 4 : 1 8 2 5 – 3 6 DES Safety in SVG PCI
1833STUDY IMPLICATIONS. Our study addresses this gap
in knowledge by demonstrating improved long-term
safety in clinical outcomes among patients receiving
DES during SVG-PCI. To the best of our knowledge,our cohort is one of the largest, with one of the
longest durations of outpatient follow-up, of any
published study on this subject. Additionally, in our
cohort, most patients receiving DES received a
TABLE 6 Continued
First Author (Ref. #)
Number of
Patients
Study Endpoints
Follow-Up
Duration Results LimitationsBMS DES
Randomized controlled trials
Brilakis et al. (4) 39 41 In-stent restenosis, death,
MI, TVR, TLR
18 months DES use associated with lower in-stent
restenosis and TLR. Other outcomes
statistically non-signiﬁcant.
Due to small sample size, lack of
power in examining clinically
relevant outcomes including
MI and death.
Jeger et al. (39) 13 34 MACE (death, MI, TVR) 18 months DES use associated with lower incidence
of MACE driven by TVR.
Secondary analysis of BASKET
randomized clinical trial.
Vermeersch et al. (6) 37 38 In-stent lumen loss, angiographic
restenosis, MACE (death, MI,
TLR, TVR)
6 months DES use associated with lower
angiographic in-stent lumen loss.
No difference in MACE.
Small sample size resulted in the
clinical trial being underpowered
for clinical outcomes.
Vermeersch et al. (7) 37 38 Mortality, MI, TVR 32 months DES associated with greater mortality
compared with BMS. No difference
in MI and TVR.
Secondary post-hoc analysis of RRISC
trial, patients on DES mandated
to receive only 3 months of dual
anti-platelet therapy.
Mehilli et al. (5) 307 303 Composite of death, MI, TLR 12 months DES associated with lower composite
of MI, death, and TLR. Incidence of
TLR lower with DES without
difference in death or MI.
Shorter follow-up duration compared
with our study.
For the search strategy, see the Online Appendix.
MACE ¼ major adverse cardiovascular events; SVG-PCI ¼ saphenous vein graft percutaneous coronary intervention; TLR ¼ target lesion revascularization; TVR ¼ target vessel revascularization;
other abbreviations as in Tables 1 and 2.
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generation DES and BMS have comparable safety.
The fact that previous observations showed a
mortality beneﬁt with DES and that second-
generation DES have safety proﬁles comparable to
BMS and ﬁrst-generation DES (40,41) may explain
why our results differ from those of previous studies.
Furthermore, our results show trends with respect
to stent type used, with close to 7 of 10 patients
receiving DES during SVG-PCI by 2011, despite a lack
of deﬁnitive evidence for their clinical safety and
effectiveness. We observed relatively lower incidence
of no-reﬂow with DES, but given the observational
nature of this dataset, this could also have resulted
from underlying, unmeasured confounders. One po-
tential confounder not accounted for in this analysis
was vein graft size, and previous reports suggested
higher incidence of no-reﬂow with larger vein grafts
(42). It is, therefore, plausible that larger vein grafts
preferentially received BMS, as they were too large
for a DES. We believe this observation is potentially
hypothesis-generating and should be explored in
subsequent analyses. These results highlight the
need for future research directed toward testing
the efﬁcacy of new generation DES compared with
BMS in patients undergoing SVG-PCI by assessing
clinically relevant outcomes rather than angiographic
differences.
STUDY LIMITATIONS. First, our cohort was
composed exclusively of U.S. veterans; this cohort is
predominantly male and has a high burden ofcomorbidities, including coronary artery disease. Our
results do not necessarily generalize to cohorts
under-represented in this study (e.g., women or non-
U.S. populations). However, most clinical trials
include VA patients, and previous coronary disease
reports showed outcomes for VA patients that were
comparable to those for non-VA patients (43). The VA
healthcare system is the largest integrated healthcare
system in the United States and provides a unique
opportunity to assess procedural characteristics and
outcomes due to the high reliability and validity of its
data sources. Second, MI event rates were potentially
underestimated, secondary to non-VA healthcare use.
We attempted to minimize this by acquiring data for
hospitalizations outside of the VA system via linkage
to fee-based ﬁles (care paid for by the VA but which
occurred outside the VA system). Third, MI outcomes
were determined using ICD-9 codes, and only a
random sample of MI patients underwent individual
chart reviews for validation in accordance with the
third universal deﬁnition of MI (11). The VA vital in-
dex ﬁle, which has a very high sensitivity for mor-
tality, was used for all-cause mortality, and ICD-9
code algorithms used in this study for MI rates were
previously validated in VA cohorts (10,12). Addition-
ally, we did not have data for cardiac mortality, spe-
ciﬁcally, and angiographic data to capture TLR or TVR
as an endpoint. We would also like to caution against
extrapolating these results toward arterial conduit
interventions, as this report focused on SVG in-
terventions. Fourth, as with all observational studies,
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The long-term
outcomes of PCI for patients with stenotic lesions in SVG are
generally worse than those associated with PCI for native coro-
nary arteries.
TRANSLATIONAL OUTLOOK: Although this propensity-
matched comparison of the use of BMS versus DES in a cohort of
veterans undergoing PCI for SVG disease suggests favorable
clinical outcomes with DES, future research should examine the
impact of later-generation DES devices on clinical outcomes
related to ischemic heart disease.
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Nonetheless, we used robust statistical methods such
as propensity scores and accounted for a large num-
ber of covariates in an attempt to minimize this.
CONCLUSIONS
These results suggest that DES use in SVG-PCI is safe
and effective in a large national cohort of veterans.
While we await results of larger randomized trials
(such as the DIVA trial) to better establish the efﬁcacy
of drug-eluting stents in SVG-PCI, these ﬁndings are
reassuring and helpful to clinicians in stent selection
during SVG-PCI.
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